In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.
Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Medtronic's cardiac and vascular group president, Michael Coyle, questions CardioMEMS' implantable heart monitor, citing Medtronic's experience with its now-abandoned Chronicle monitor.
The Champion implantable heart monitor made by CardioMEMS might not prove as cost-effective as a non-invasive approach, at least according to Medtronic (NYSE:MDT) cardiac and vascular group president Michael Coyle.
ResMed says it acquired Czech distributor Unimedis for an undisclosed amount.
ResMed (NYSE:RMD) said it bought out Czech medtech distributor Unimedis for an undisclosed amount.
Prague-based Unimedis specializes in sleep-disordered breathing and respiratory care devices in the Czech Republic and Slovakia. Unimedis co-founder Ondrej Kalas will stay on as the country manager for ResMed, according to a press release.